Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Bionano Genomics says Saphyr System able to analyze 'segmental duplications' » 16:35
10/15/20
10/15
16:35
10/15/20
16:35
BNGO

Bionano Genomics

$0.58 /

-0.0113 (-1.92%)

Bionano Genomics…

Bionano Genomics announced that a study led by scientists and clinicians from the Institute for Human Genetics at the UCSF School of Medicine and the Department of Pediatrics at the University of Colorado School of Medicine and published in bioRxiv used Bionano's proprietary genome imaging technology to identify novel disease causing variants in patients with three different genetic diseases and in a diverse control dataset of 154 individuals. The study found that Bionano's Saphyr System was able to comprehensively analyze complex genome structures called segmental duplications and helped identify several novel structural variations associated with each disease causing locus increasing the understanding of these diseases. Segmental duplications are large segments of repetitive sequences tens to hundreds of thousands of base pairs in size. Short-read and long-read sequencing technologies cannot span these large segments of the genome. Only Bionano's optical mapping technology can image single molecules that are so long that they span the segmental duplications. These repetitive sequences can interact with each other when sperm or eggs are created and their rearrangement can cause severe genetic disease. Some of the most common of such diseases are microdeletions at 7q11.23, also known as Williams-Beuren syndrome, 15q13.3 microdeletion syndrome, 16p12.2 microdeletion syndrome and 22q11.2 deletion syndrome, also known as DiGeorge syndrome.

ShowHide Related Items >><<
BNGO Bionano Genomics
$0.58 /

-0.0113 (-1.92%)

BNGO Bionano Genomics
$0.58 /

-0.0113 (-1.92%)

09/24/20 Ladenburg
Bionano Genomics initiated with a Buy at Ladenburg
04/08/20 Oppenheimer
Oppenheimer bullish on Bionano Genomics, initiates with an Outperform
04/08/20 Oppenheimer
Bionano Genomics initiated with an Outperform at Oppenheimer
BNGO Bionano Genomics
$0.58 /

-0.0113 (-1.92%)

Earnings
Bionano Genomics sees Q3 revenue $1.9M-$2.3M, consensus $2.07M  08:17
10/15/20
10/15
08:17
10/15/20
08:17
BNGO

Bionano Genomics

$0.59 /

+0.0013 (+0.22%)

 
ShowHide Related Items >><<
BNGO Bionano Genomics
$0.59 /

+0.0013 (+0.22%)

BNGO Bionano Genomics
$0.59 /

+0.0013 (+0.22%)

09/24/20 Ladenburg
Bionano Genomics initiated with a Buy at Ladenburg
04/08/20 Oppenheimer
Oppenheimer bullish on Bionano Genomics, initiates with an Outperform
04/08/20 Oppenheimer
Bionano Genomics initiated with an Outperform at Oppenheimer
BNGO Bionano Genomics
$0.59 /

+0.0013 (+0.22%)

Over a week ago
Hot Stocks
Bionano Genomics announces publication on Bionano's Saphyr » 08:16
10/08/20
10/08
08:16
10/08/20
08:16
BNGO

Bionano Genomics

$0.61 /

-0.0053 (-0.86%)

Bionano Genomics…

Bionano Genomics announced that its Saphyr system played a key role in a research study by Marcin Imielinski, M.D., Ph.D., Assistant Professor of Pathology and Laboratory Medicine at Weill Cornell Medical School, which was published in the peer-reviewed journal Cell. The study identified three new distinct classes of structural variations in the DNA of thousands of cancer samples across multiple cancer types, and used Saphyr to characterize the precise structure and genomic location of these variations. These previously unknown types of complex rearrangements help explain different mechanisms that enable cancer cells to expand and grow rapidly while simultaneously evading natural defense mechanisms and treatment. With the addition of Bionano's Saphyr data, the study demonstrated that these structural variants generate a large number of fusion proteins and represent therapeutic targets and/or prognostic biomarkers of disease progression. While cancer genomes traditionally have been studied with a combination of low-resolution cytogenetic methods or with next-generation sequencing, Bionano's Saphyr instrument provides long-range data that enables a high-resolution, long-range view into the cancer genome and cancer biology. At a presentation providing an update on the study given at the March 31, 2020 Advances in Genome Biology and Technology Conference, Dr. Imielinski explained how short-read data alone is unable to resolve the structure of these newly discovered structural variants because short reads provide a very local view of the genome, and further explained how integrating long-range data generated by Bionano's optical mapping technology was essential to obtaining a complete understanding of these structures, including their biological significance. As previously announced, a high-profile paper published last month by UCSD Professor Vineet Bafna in Nature Communications similarly used a combination of NGS and Bionano's Saphyr data to resolve the structure of extra-chromosomal circular DNA, another type of complex rearrangement of the cancer genome which similarly allows for tumor cells to increase their growth rate while evading natural defenses. In both studies, only the combination of short-read sequencing technology with optical mapping data generated by Saphyr was able to fully resolve these complex structures and provide a comprehensive picture of the cancer genome.

ShowHide Related Items >><<
BNGO Bionano Genomics
$0.61 /

-0.0053 (-0.86%)

BNGO Bionano Genomics
$0.61 /

-0.0053 (-0.86%)

09/24/20 Ladenburg
Bionano Genomics initiated with a Buy at Ladenburg
04/08/20 Oppenheimer
Oppenheimer bullish on Bionano Genomics, initiates with an Outperform
04/08/20 Oppenheimer
Bionano Genomics initiated with an Outperform at Oppenheimer
BNGO Bionano Genomics
$0.61 /

-0.0053 (-0.86%)

Hot Stocks
Bionano Genomics stockholders vote in favor of increasing authorized shares » 16:10
09/30/20
09/30
16:10
09/30/20
16:10
BNGO

Bionano Genomics

$0.64 /

+0.0447 (+7.48%)

Bionano Genomics, Inc.…

Bionano Genomics, Inc. announced that its stockholders have voted in favor of the company's proposal to increase the number of its authorized shares of common stock. "We appreciate the support of our stockholders on this critically important proxy proposal," said Erik Holmlin, Ph.D., chief executive officer of Bionano Genomics. "We now look forward to continuing to execute upon our strategy."

ShowHide Related Items >><<
BNGO Bionano Genomics
$0.64 /

+0.0447 (+7.48%)

BNGO Bionano Genomics
$0.64 /

+0.0447 (+7.48%)

09/24/20 Ladenburg
Bionano Genomics initiated with a Buy at Ladenburg
04/08/20 Oppenheimer
Oppenheimer bullish on Bionano Genomics, initiates with an Outperform
04/08/20 Oppenheimer
Bionano Genomics initiated with an Outperform at Oppenheimer
BNGO Bionano Genomics
$0.64 /

+0.0447 (+7.48%)

Hot Stocks
Bionano Genomics announces adoption of Saphyr system in Australia and Slovenia » 17:55
09/29/20
09/29
17:55
09/29/20
17:55
BNGO

Bionano Genomics

$0.60 /

+0.0015 (+0.25%)

Bionano Genomics…

Bionano Genomics announced that its Saphyr system has been adopted through reagent-rental agreements by two renowned institutions in Australia and Slovenia: the Royal North Shore Hospital in Northern Sydney, New South Wales, Australia; and the University Medical Center Ljubljana in Ljubljana, Slovenia. Both hospitals aim to assess Saphyr's potential for diagnosing leukemias as compared to current standards of care, including karyotyping, chromosomal microarray and fluorescence in situ hybridization, or FISH.

ShowHide Related Items >><<
BNGO Bionano Genomics
$0.60 /

+0.0015 (+0.25%)

BNGO Bionano Genomics
$0.60 /

+0.0015 (+0.25%)

09/24/20 Ladenburg
Bionano Genomics initiated with a Buy at Ladenburg
04/08/20 Oppenheimer
Oppenheimer bullish on Bionano Genomics, initiates with an Outperform
04/08/20 Oppenheimer
Bionano Genomics initiated with an Outperform at Oppenheimer
BNGO Bionano Genomics
$0.60 /

+0.0015 (+0.25%)

Hot Stocks
MVZ Martinsried receives accreditation for use of Bionano's Saphyr System » 08:15
09/24/20
09/24
08:15
09/24/20
08:15
BNGO

Bionano Genomics

$0.59 /

-0.0342 (-5.48%)

Bionano Genomics…

Bionano Genomics announced that MVZ Martinsried received accreditation for use of Bionano's digital cytogenetics platform, Saphyr, for laboratory developed tests as an important component of their testing services moving forward. Approval was awarded by Deutsche Akkreditierungsstelle, the national accreditation body for the Federal Republic of Germany, following the one of the most stringent review process in Europe. The approval accredits LDTs developed by MVZ Martinsried for the detection of the following types of structural variants: translocations, inversions and duplications. Translocations, for example, cause different forms of leukemia and myeloma, including chronic myelogenous leukemia and multiple myeloma, and different forms of solid tumor cancers, including non-small cell lung cancer. Inversions and duplications are also often implicated in cancers and all three types are known to occur in constitutional genetic disorders. These so-called balanced genome rearrangements are challenging to detect by sequencing and microarrays, yet the standard of care for detecting them is karyotyping and fluorescence in situ hybridization. Genome analysis with Saphyr consolidates into a single assay the SV detection capabilities, including balanced rearrangements, of three separate structural variant analysis techniques.

ShowHide Related Items >><<
BNGO Bionano Genomics
$0.59 /

-0.0342 (-5.48%)

BNGO Bionano Genomics
$0.59 /

-0.0342 (-5.48%)

09/24/20 Ladenburg
Bionano Genomics initiated with a Buy at Ladenburg
04/08/20 Oppenheimer
Oppenheimer bullish on Bionano Genomics, initiates with an Outperform
04/08/20 Oppenheimer
Bionano Genomics initiated with an Outperform at Oppenheimer
BNGO Bionano Genomics
$0.59 /

-0.0342 (-5.48%)

Initiation
Bionano Genomics initiated with a Buy at Ladenburg » 06:42
09/24/20
09/24
06:42
09/24/20
06:42
BNGO

Bionano Genomics

$0.59 /

-0.0342 (-5.48%)

Ladenburg initiated…

Ladenburg initiated coverage of Bionano Genomics with a Buy rating and $1.25 price target.

ShowHide Related Items >><<
BNGO Bionano Genomics
$0.59 /

-0.0342 (-5.48%)

BNGO Bionano Genomics
$0.59 /

-0.0342 (-5.48%)

04/08/20 Oppenheimer
Oppenheimer bullish on Bionano Genomics, initiates with an Outperform
04/08/20 Oppenheimer
Bionano Genomics initiated with an Outperform at Oppenheimer
BNGO Bionano Genomics
$0.59 /

-0.0342 (-5.48%)

Over a month ago
Hot Stocks
Bionano Genomics announces results generated with Saphyr relating to ALS, DM » 08:10
09/17/20
09/17
08:10
09/17/20
08:10
BNGO

Bionano Genomics

$0.59 /

-0.0059 (-0.99%)

Bionano Genomics…

Bionano Genomics announced that teams from the Mayo Clinic and from the University of Florida have separately released results generated with Saphyr relating to Amyotrophic Lateral Sclerosis and Myotonic Dystrophy, respectively, two severe genetic disorders caused by the expansion of repetitive sequences in the genome. Saphyr identified repeat expansions in patients with ALS and DM that were so large that only Saphyr is capable of sizing them correctly. These findings help increase understanding of the disease-causing mechanisms and may lead to better diagnostic tests, support direct drug development and facilitate better identification of patients who are likely to respond to treatment. In a study published in bioRxiv, a team led by Dr. Eric Wang from the University of Florida used Saphyr to identify genomic variants that determine the severity of neurological symptoms caused by DM. These symptoms, caused by an abnormal processing of a number of brain-expressed genes, correlate with the length of a repeat expansion. The study helped demonstrate that ultra-long DNA analysis technology, such as Bionano's Saphyr, is crucial to enabling the accurate measurement of these repeat expansions. Separately, in an online presentation by Dr. Mark Ebbert from the Mayo Clinic, Saphyr data was used to measure the repeat expansion in the C9ORF72 gene that causes ALS. A large number of repeat sizes were detected in the brains of individual ALS patients, demonstrating how the expanded repeat is unstable and leads to increasingly large expansions. The amount of variation within individuals was previously underestimated due to the lack of accurate measurement techniques. In both cases, the disease-causing repeats were found to be tens of thousands of basepairs in length, too long to be accurately measured by currently available short-read and even long-read sequencing technologies. Additionally, the amount of variation within individual brain samples requires a single-molecule analysis method, like Bionano's genome imaging. The studies provide additional support for the utility of Bionano's single molecule, ultra-long DNA analysis technology in advanced disease research. In contrast, current diagnostic tests for large repeat expansions like the ones typically involved in DM and ALS are imprecise, lack the resolution and sensitivity to determine the size of the expansion and typically require confirmation with outdated methods like Southern Blot.

ShowHide Related Items >><<
BNGO Bionano Genomics
$0.59 /

-0.0059 (-0.99%)

BNGO Bionano Genomics
$0.59 /

-0.0059 (-0.99%)

04/08/20 Oppenheimer
Oppenheimer bullish on Bionano Genomics, initiates with an Outperform
04/08/20 Oppenheimer
Bionano Genomics initiated with an Outperform at Oppenheimer
BNGO Bionano Genomics
$0.59 /

-0.0059 (-0.99%)

Hot Stocks
Bionano's Saphyr system adopted through reagent-rentals at four institutions » 08:24
09/16/20
09/16
08:24
09/16/20
08:24
BNGO

Bionano Genomics

$0.59 /

+0.0432 (+7.97%)

Bionano Genomics…

Bionano Genomics announced that its Saphyr system has been adopted through reagent-rentals by four additional institutions in Europe: the Department of Human Genetics, Ruhr University Bochum and the Clinic for Pediatrics III, University Hospital Essen in Germany and the Institute for Medical Genetics and Pathology at the University Hospital Basel and the Institute for Medical Genetics, Zurich in Switzerland. At each medical institute, integration of Bionano's Saphyr will be used to help validate Bionano's genome imaging technology against standard methods in cytogenetic analysis as a path to streamline the diagnostics workflow for constitutional genetic conditions and for cancer diagnostics. Genome analysis with Saphyr consolidates into a single assay the testing that typically requires three separate structural variant analysis techniques. With its demonstrated sensitivity as low as approximately 1% allele fraction, we believe Saphyr meets or exceeds the performance requirements to help drive adoption.

ShowHide Related Items >><<
BNGO Bionano Genomics
$0.59 /

+0.0432 (+7.97%)

BNGO Bionano Genomics
$0.59 /

+0.0432 (+7.97%)

04/08/20 Oppenheimer
Oppenheimer bullish on Bionano Genomics, initiates with an Outperform
04/08/20 Oppenheimer
Bionano Genomics initiated with an Outperform at Oppenheimer
BNGO Bionano Genomics
$0.59 /

+0.0432 (+7.97%)

Hot Stocks
Bionano Genomics launches Lineagen EpiPanelDx PLUS gene panel test » 08:29
09/14/20
09/14
08:29
09/14/20
08:29
BNGO

Bionano Genomics

$0.51 /

-0.0209 (-3.94%)

Bionano Genomics…

Bionano Genomics announced the release of EpiPanelDx PLUS by its diagnostics services business, Lineagen. The new laboratory developed test and associated clinical support bolsters Lineagen's diagnostic services for physicians providing care for pediatric patients with neurodevelopmental disorders. EpiPanelDx PLUS is based on a proprietary panel of 223 genes associated with epilepsy-related conditions, more genes than typically found on epilepsy panels available from other service providers and customized for Lineagen's core market of neurodevelopmental disorders. Epilepsy refers to an array of neurological disorders characterized by involuntary seizures and affects approximately 1.2% of the population, or 3.4 million people, in the United States. It is frequently comorbid with other NDDs of childhood development, including intellectual disability and autism spectrum disorder and also can co-occur with neuro-behavioral disorders such as attention deficit hyperactivity disorder. Collectively, NDDs represent the most common form of developmental disorder with an estimated prevalence of 1 out of 6 children affected in industrialized countries. Lineagen's current menu of FirstStepDx PLUS chromosomal microarray and NextStepDx PLUS whole exome sequencing offers leading molecular diagnostic tests designed to help pediatricians and pediatric neurodevelopmental specialists manage their patients with NDDs. Offering such physicians a test for epilepsy allows Lineagen to more comprehensively serve their needs. EpiPanelDx PLUS is designed for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures, and has an expected 30% diagnostic yield. Lineagen also offers testing to the parents of the patients. By including the analysis of the genomes of one or both biological parents of the patient from the start, it is possible to increase the detection rate of disease-causing variants and inform on recurrence risk for the family. EpiPanelDx PLUS has been curated based on thorough literature review and includes genes with pathogenic variants identified in more than 2,000 epileptic patients tested by Lineagen. The use of a targeted gene panel such as EpiPanelDx PLUS fits the testing strategy that is recommended by the American Academy of Neurology and complements existing genetic tests offered by Lineagen such as FirstStepDx PLUS chromosomal microarray and NextStepDx PLUS whole exome sequencing, which are recommended for patients who show a wider array of neurological symptoms. To help tailor medical management, Lineagen also offers pharmacogenomic testing which includes certain genes that are responsible for the metabolism of important anti-epileptic or anticonvulsant drugs prescribed for epilepsy.

ShowHide Related Items >><<
BNGO Bionano Genomics
$0.51 /

-0.0209 (-3.94%)

BNGO Bionano Genomics
$0.51 /

-0.0209 (-3.94%)

04/08/20 Oppenheimer
Oppenheimer bullish on Bionano Genomics, initiates with an Outperform
04/08/20 Oppenheimer
Bionano Genomics initiated with an Outperform at Oppenheimer
BNGO Bionano Genomics
$0.51 /

-0.0209 (-3.94%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.